Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEV102 in acquired blepharoptosis
NCT05715346Phase 2Completed
- Sponsor
- Levation Pharma
- Start
- Feb 2023
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of LEV-102 in acquired blepharoptosis, sponsored by Levation Pharma. Started Feb 2023; status: completed.
02
Drugs
LEV-102
03
Conditions
acquired blepharoptosis
Beyond the preview
Go deeper on NCT05715346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05715346.